TARA MEXC RealStocks
Own real TARA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:11:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Protara Therapeutics, Inc. (TARA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.33, with a market capitalization of $142.84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.09 to $7.82. This page covers its latest market performance, valuation, price trends and company information.
$142.84M | |
$2.31 | |
$2.40 | |
$2.26 | |
$2.32 | |
1.00M | |
1.05M | |
-- | |
$7.82 | |
$2.09 | |
-- | |
2026-09-30 |
Protara Therapeutics, Inc. (TARA) last closed at $2.33 as of 2026-11-19 00:46:00, up 0.86% ($0.02) from the previous close of $2.32.
During the latest regular trading session, TARA traded between $2.26 and $2.41, with a volume of 1.00M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Protara Therapeutics, Inc. (TARA) moved from $2.43 to $2.33, representing a decline of 3.95% ($0.10).
The stock traded between $2.25 and $2.70 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 799.63 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.3%
TARA is currently trading at $2.33, placing it 4.3% of the way from its 52-week low of $2.09 to its 52-week high of $7.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 51 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Protara Therapeutics, Inc. (TARA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TARA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TARA shares and USD.
TARA Shares to USD
1.00 TARA shares = 2.334 USD
Calculations are estimates based on the latest available price and are for reference only.